The Analysis Results Standard (ARS) is a CDISC standard for the machine-readable description of analysis results from clinical trials. It does not model the input data for an analysis, but rather the content of tables, figures, listings, and other result presentations, including the associated metadata. ARS is intended to enable the automation, reuse, reproducibility, and traceability of such results.
This enables a structured chain from the specified result to its reusable presentation.
Results as data objects rather than just report layouts
In clinical trials, many result presentations are created as files for the clinical study report, submission dossiers, or internal decision-making. However, a table layout alone contains only limited information about which population, variable, grouping, statistic, and input data led to a result. ARS describes these subject-matter elements separately from the mere appearance of a page.
The standard focuses on the outcome of an analysis operation. A mean by treatment group, a frequency of adverse events, or a plot of change over time can be represented as structured results with relationships to analyses, variables, and subsets. This allows a system to recognize the substantive message conveyed by a table, even if it is later output in a different layout.
Position between ADaM and reporting
ARS sits in the data flow after the analysis datasets have been provided. ADaM contains the analysis-ready data from which programs calculate results; ARS models the produced results and their descriptive information. The standard therefore links the level of analysis programs and datasets with the reusable building blocks of results reporting.
CDISC documentation assigns the standard a logical model and a user guide. The logical model describes analysis results and metadata; the guide illustrates usage using common safety outputs. This does not prescribe which conclusions a study must deliver. What matters instead is how already defined results are represented so that their origin and meaning remain technically traceable.
Machine-readable result information can be particularly helpful for safety tables when similar analyses are compared across multiple data cuts or across studies. The model allows content characteristics such as the analyzed variable, the target population, the treatment, and the summary used to be explicitly specified. For automated production, this information is more meaningful than a table image whose column headings alone do not disclose all rules.
ARS was released on April 19, 2024, as version 1.0. In addition to the standard, the CDISC release includes a user guide, model documentation, and supporting files. For project teams, this means mapping existing TLF conventions to the concepts available in the model, rather than reconstructing the content specification solely by working backwards from a final report document.
Scope: a data model for results, not a document
ARS is not a clinical study report and does not replace a table in the final PDF. The Clinical Study Report remains a regulatory document with a defined narrative and tabular presentation. ARS structures the resulting content so that it can be processed by software, linked, and reused across different outputs.
ARS also does not replace the Statistical Analysis Plan. The plan defines objectives, endpoints, and statistical methods in advance; the standard can link later analysis results to these specifications. ADaM remains the level for datasets on which calculations are performed. ARS describes what results from those calculations and which analysis characteristics explain the result.
Traceability does not end with the program output: for critical results, it should be clear which data cut, which rule, and which approved analysis version they are based on.
Relevance for clinical trials
ARS is particularly relevant when a program is intended to generate and validate recurring tables, figures, and listings consistently across multiple studies. To do so, TLF specifications must clearly distinguish between content concepts, such as analysis population or parameter, and pure layout requirements. Without this separation, it is difficult to compare identical substantive results across different reports, studies, or systems. Quality assurance can then more specifically verify whether an output matches the specified analysis.
Full-service CROs such as Mediconomics support ARS-aligned processes by structuring TLF specifications, mapping them to the analysis plan and ADaM datasets, validating statistical programs, and producing tables, figures, and listings in a controlled manner. They can also coordinate the handover of result data to Medical Writing so that statements in the clinical study report align with the approved analysis outputs.
Frequently Asked Questions (FAQ)
Does ARS standardize the appearance of every results table?
No. The focus is on the subject-matter concepts and metadata of a result, not on a uniform page design or font formatting.
Does ARS require ADaM?
ARS describes analysis results, while ADaM provides analysis-ready datasets. In a typical CDISC chain, both levels are closely linked, but they remain separate standards.
Can ARS automatically write a Clinical Study Report?
The standard can support the structured reuse of result information. Medical interpretation and the creation of a regulatorily complete report remain separate tasks.
Regulatory References
- CDISC Analysis Results Standard v1.0 – publishes the logical model and accompanying materials for analysis results.
- CDISC Analysis Data Model – defines the analysis-ready data structures on which results are calculated.
- CDISC Define-XML – supports the description of dataset and analysis metadata for submissions.
- FDA Study Data Technical Conformance Guide – places analyzable study data and its metadata in the submission context.
